You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

CANCIDAS Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Cancidas patents expire, and when can generic versions of Cancidas launch?

Cancidas is a drug marketed by Merck and is included in one NDA.

The generic ingredient in CANCIDAS is caspofungin acetate. There are eight drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the caspofungin acetate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Cancidas

A generic version of CANCIDAS was approved as caspofungin acetate by FRESENIUS KABI USA on December 30th, 2016.

  Try a Trial

Drug patent expirations by year for CANCIDAS
Drug Prices for CANCIDAS

See drug prices for CANCIDAS

Recent Clinical Trials for CANCIDAS

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Cidara Therapeutics Inc.Phase 3
CttqPhase 2
Cidara Therapeutics Inc.Phase 2

See all CANCIDAS clinical trials

Pharmacology for CANCIDAS
Paragraph IV (Patent) Challenges for CANCIDAS
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
CANCIDAS for Injection caspofungin acetate 50 mg/vial and 70 mg/vial 021227 1 2009-06-26

US Patents and Regulatory Information for CANCIDAS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck CANCIDAS caspofungin acetate POWDER;INTRAVENOUS 021227-001 Jan 26, 2001 AP RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Merck CANCIDAS caspofungin acetate POWDER;INTRAVENOUS 021227-002 Jan 26, 2001 AP RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CANCIDAS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck CANCIDAS caspofungin acetate POWDER;INTRAVENOUS 021227-001 Jan 26, 2001 ⤷  Try a Trial ⤷  Try a Trial
Merck CANCIDAS caspofungin acetate POWDER;INTRAVENOUS 021227-002 Jan 26, 2001 ⤷  Try a Trial ⤷  Try a Trial
Merck CANCIDAS caspofungin acetate POWDER;INTRAVENOUS 021227-002 Jan 26, 2001 ⤷  Try a Trial ⤷  Try a Trial
Merck CANCIDAS caspofungin acetate POWDER;INTRAVENOUS 021227-002 Jan 26, 2001 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for CANCIDAS

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0620232 C300076 Netherlands ⤷  Try a Trial PRODUCT NAME: CASPOFUNGINE, DESGEWENST IN DE VORM VAN EEN ZUURADDITIEZOUT, IN HET BIJZONDER CASPOFUNGINE ACETAAT; REGISTRATION NO/DATE: EU/1/01/196/001-003 20011024
0620232 SPC029/2001 Ireland ⤷  Try a Trial SPC029/2001: 20031204, EXPIRES: 20161023
0620232 SPC/GB02/002 200210 United Kingdom ⤷  Try a Trial
0620232 2001/029 Ireland ⤷  Try a Trial PRODUCT NAME: CASPOFUNGIN, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY CASPOFUNGIN ACETATE; REGISTRATION NO/DATE: EU/1/01/196/001-003 20011024; PAEDIATRIC INV. PLAN: P/30/2008
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.